In more than 95% of the health centers in our country, molecular diagnosis is not performed in patients with thyroid cancer
One in five patients could benefit from the incorporation of RET inhibitors, targeted drugs that have given response rates of 70% in patients with metastatic thyroid cancer
In addition to RET alterations, there are others like those that affect the BRAF, NTRK or mTOR genes, which in total may affect 80% of patients with differentiated thyroid cancer, the most common subtype